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ABSTRACT 
Novel alternatives to antibiotics are urgently needed for the successful treatment of antimicrobial resistant 
(AMR) infections. Experimental antibacterial oligonucleotide therapeutics, such as transcription factor 
decoys (TFD), are a promising approach to circumvent AMR. However, the therapeutic potential of TFD 
is contingent upon the development of carriers that afford efficient DNA protection against nucleases and 
delivery of DNA to the target infection site. As a carrier for TFD, here we present three prototypes of 
anionic solid lipid nanoparticles that were coated with either the cationic bolaamphiphile 12-bis-
tetrahydroacridinium or with protamine. Both compounds switched particles zeta potential to positive 
values, showing efficient complexation with TFD and demonstrable protection from deoxyribonuclease. 
The effective delivery of TFD into bacteria was confirmed by confocal microscopy while SLN-bacteria 
interactions were studied by flow cytometry. Antibacterial efficacy was confirmed using a model TFD 
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targeting the Fur iron uptake pathway in E.coli under microaerobic conditions. Biocompatibility of TFD-
SLN was assessed using in vitro epithelial cell and in vivo Xenopus laevis embryo models. Taken together 
these results indicate that TFD-SLN complex can offer preferential accumulation of TFD in bacteria and 
represent a promising class of carriers for this experimental approach to tackling the worldwide AMR 
crisis. 
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INTRODUCTION 
Antimicrobials have been a marked success in modern medicine, greatly reducing death and morbidity 
associated with bacterial infections. However, the antibiotic era is widely thought to be coming to an end 
due to their overuse or misuse in the clinic. Strains of bacteria have developed multiple-drug resistance 
(MDR) and are no longer treatable [1]. Conventional pharmaceutical approaches have failed to discover 
any new class of antimicrobials for 30 years and there is now a pressing need to develop alternatives to 
conventional antimicrobials [2, 3]. Alternative strategies include oligonucleotide therapeutics that have 
the advantages of not being susceptible to resistance mechanisms to standard antibiotics and acting on 
novel therapeutic targets, such as transcription, that up to now have been undruggable. Moreover, 
targeting non-essential genes should further reduce the possibility of resistance development [4, 5]. Due 
to the large size, high anionic charge and hydrophilic nature of native oligonucleotides (ON) they are 
unable to cross the membranes of bacteria to reach their targets. Hence the challenge of efficient delivery 
must be faced to develop ON therapeutics. Optimal delivery system should encapsulate the ON with high 
efficiency and protect them from degradation, should not trigger immunogenic reactions in the host and 
be safe [6]. Typically ON antimicrobials are conjugated with cationic moieties, like cell penetrating 
peptides (CPP), which are naturally charged and bind readily to bacterial membranes [7]. However, CPP 
use is limited to highly modified antisense ON, which have neutrally charged backbones, otherwise they 
would cause negatively charged ON precipitation [8] These conjugates show efficacy in in vitro and in 
vivo models of bacterial infections but only at relatively high concentrations, which has limited their 
development, also due to high cytotoxicity [9, 10]. Other interesting cationic compound for ON delivery 
include dequalinium, a well-known drug with antimicrobial activity, which has been described for its 
ability to form self-assembled structures that efficiently bind DNA and afford high transfection 
efficiencies in bacteria [11]. In this regard, a recently described bolaamphiphilic molecule with analogous 
structure, 1,1'-(dodecane-1,12-diyl)-bis-(9-amino-1,2,3,4-tetrahydroacridinium) chloride (12-bis-THA or 
simply THA), showed a strong affinity towards cardiolipin, which plays an important role in the dynamic 
organization of bacterial membranes, and effectively delivers ON into Clostridium difficile in an animal 
model [12]. ON and 12-bis-THA form nanoparticles with sizes between 90 and 400 nm depending on the 
  
structure of the ON; however, these nanoparticles can be prepared only as a dilute suspension and they 
showed poor stability in physiological conditions, as well certain cytotoxicity [13].  
Solid lipid nanoparticles (SLN) are versatile carriers which can be designed for nucleic acids delivery 
[14-16], with several advantages: their production is relatively simple and scalable, they have long term 
stability and they can be sterilized by filtration. Furthermore, SLN can be administered by different routes 
and show very favorable toxicity profiles. It is even possible to control the release of associated cargo by 
modification of SLN lipid matrix [16]. As applied in other nucleic acid delivery systems, SLN surfaces 
can be modified to introduce positive charge and establish electrostatic interaction with negatively 
charged nucleic acids, so favoring its condensation and penetration into target cells [17], i.e. ON-SLN 
complexes can be obtained by simple incubation of ON with cationic SLN. ON-SLN-mediated 
transfection has been previously reported by several researchers, both in vitro (eukaryotic cells) [18, 19] 
and in vivo models [18, 20, 21]. 
To address the issues described above, we investigated whether THA coated SLN can retain sufficient 
complexation with antibacterial ON to form stable lipid-based complex, and whether it is possible to 
optimize ratio THA/ON whilst retaining biological activity. We studied Transcription Factor Decoys 
(TFD) as antibacterial ON: they are short double stranded DNA molecules that act on novel genomic 
targets by capturing key regulatory proteins to block essential bacterial genes and defeat infection [22]. In 
this study two different TFD were used: SigH, which specifically blocks the key sigma factor of transition 
phase in C. difficile, and the Ferric Uptake Regulator (Fur), which controls import of the essential 
micronutrient iron into E. coli under limiting conditions: growth of E. coli lacking Fur is normal in iron 
rich media but is severely inhibited in iron depleted media [23]. 
 
MATERIAL AND METHODS 
Materials 
Cholesteryl acetate, cholesteryl palmitate, 2-phenylethanol, polyoxyethylene (40) stearate, protamine 
sulfate salt from Herring (Grade III), heparin sodium salt and phosphate buffered saline (PBS, pH 7.4) 
were purchased from Sigma-Aldrich (Italy), while cholesteryl butyrate was from TCI chemicals Europe 
(Belgium). Epikuron
®
200 (92% phosphatidylcholine) (PC) (Cargill, Italy) was supplied by ACEF (Italy), 
which was also the supplier for ascorbyl palmitate and butyl alcohol, while sodium taurocholate was 
acquired from PCA (Italy). Fluorescent probes DiO (3,3dioctadecyloxacarbocyanine), DiD (1,1'-
dioctadecyl-3,3,3',3'tetramethylindodicarbocyanine), and DiI (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine) (Biotium, USA) were purchased from VWR (Italy), as well nucleic acid 
gel stain Gel Red
®
  (Biotium, US). Dynasan
®
 116 was kindly given by Cremer Oleo Division (Germany). 
Sepharose CL-4B was purchased from Sigma-Aldrich (Italy). The 12-bis-THA (THA) was synthesized 
by Shanghai Chempartner Co. Ltd. Reagents used for gel electrophoresis were purchased from several 
suppliers, agarose DNA grade from VWR (Italy), TBE 10X from Amresco (USA), and Xylene Cyanol 
  
and Bromophenol Blue from Merck (Italy). All organic solvents, HPLC grade, were purchased from 
Merck (Italy). 
Bacterial growth media, culture plasticware, poly-lysine coated microscopy glass slides, and 
Fluoroshield
®
 mounting media were obtained from Sigma Aldrich (UK); the McFarland turbidity 
standard and the wheat germ agglutinin lectin membrane dye conjugated with tetra-methyl rhodamine 
fluorescent and with AlexaFluor
®
 647 were purchased from ThermoFisher (UK). 
All TFD were manufactured and purified by HPLC at AxoLabs (Kulmbach, Germany). The SigH 
dumbbell TFD (SigH DB TFD), used mainly for SLN development and characterization, consists of 77 
bp, whereas the Ferric Uptake Regulator hairpin TFD (Fur HP TFD), which was selected for efficacy 
proof of concept in E.coli, comprises 59 bases (See supplementary material for complete sequences). 
AlexaFluor
®
 488 fluorescent dye (λex/em=495/519 nm) was attached to the 5’ end for fluorescent labelling 
(AF488 Fur HP TFD), needed to study interactions between TFD-SLN complexes and bacteria by 
fluorescence microscopy. 
All oligonucleotides were resuspended in distilled Nuclease-Free water at concentration of 0.5 µM, 
annealed by heating at 95 °C for 2 minutes and allowed to cool to room temperature for 15 minutes. They 
were then purified by ethanol precipitation, resuspended again in distilled RNase-free water and stored at 
-20
o
C until use. 
1. SLN preparation 
1.1 Anionic SLN  
Anionic SLN were prepared by oil-in-water (O/W) warm microemulsion method reported elsewhere 
[24, 25]. Briefly, the selected lipid matrix was heated above its melting point, then it was mixed under 
magnetic stirring with an aqueous phase at the same temperature containing surfactants 
(phosphatidylcholine and polyoxyethylene (40) stearate)  and co-surfactants (sodium taurocholate, butyl 
alcohol and 2-phenyl ethanol) in an appropriate mixture to stabilize O/W interface and promote 
spontaneous microemulsion formation. The microemulsion was immediately dispersed into water at 2–
3°C (ratio 1:10 v/v) under mechanical stirring (1900 rpm). 3 anionic SLN prototypes were obtained 
depending on matrix composition: A-Chol (cholesteryl esters mixture), A-TP (tripalmitin) and A-TPAP 
(tripalmitin and ascorbyl palmitate mixture). Obtained SLN dispersions were then washed (6X) by 
tangential flow filtration (TFF) (Vivaflow 50, RC membrane, 100 KDa MWCO, Sartorius Stedim Biotech 
GmbH, Italy) for purification, all components were finally reduced at regulatory acceptable 
concentrations [26]. 
 
1.2. TFD-THA-SLN complexes preparation 
12-bis-THA (THA) and TFD (oligonucleotides, ON) were added to preformed SLN by a coating 
technique, exploiting electrostatic interaction. Briefly, THA saturated aqueous solution (800 µg/mL) was 
added drop by drop into anionic SLN dispersions under magnetic stirring, in a ratio 1:1.5 (v/v). After 15 
  
minutes of incubation, obtained dispersion was washed (3X) by tangential flow filtration membrane in 
order to remove free THA. Filterability of THA through used membrane was previously assessed to 
ensure effectiveness of this washing process.  
Cationic THA coated SLN (C-Chol and C-TP SLN respectively) were then incubated in orbital shaker 
(400 rpm, 30 minutes) with TFD aqueous solution to achieve different TFD final concentrations (10-160 
µg/mL) obtaining cationic THA-SLN complexed with oligonucleotides: ON-C-Chol and ON-C-TP SLN.  
In order to ameliorate TFD interaction with the carriers, other formulations were prepared with a 
second layer of THA onto previous TFD layer (C-ON-C-Chol and C-ON-C-TP respectively), by simple 
adding a small volume (100 µL) of THA aqueous solutions at different concentrations (100 to 320 
µg/mL) to ON-C-Chol and ON-C-TP prototypes. Final washing was carried out by tangential flow 
filtration, as previously described. 
Finally, as a control, a different type of cationic SLN (C-TPAP SLN) were prepared by substituting 
THA with the cationic polypeptide protamine as SLN coating. Similarly, protamine aqueous solution (2 
mg/mL) was poured drop by drop onto anionic SLN dispersion (A-TPAP) under magnetic stirring, in a 
ratio 1:5 (v/v). Tangential flow filtration (3X) was performed after 15 minutes of incubation to remove 
free protamine. Finally, cationic protamine-SLN were incubated with TFD aqueous solutions in order to 
achieve different TFD final concentrations (10-160 µg/mL) (ON-C-TPAP). Table 1 summarizes SLN 
codification according to layers and composition. Fluorescent SLN for further SLN characterization and 
for uptake studies by confocal microscopy were prepared by adding hydrophobic fluorophores DiO, DiI 
or DiD to the oily phase of microemulsion, at molar percentage of PC (2%). 
 
2. SLN characterization 
Several techniques were used to characterize obtained SLN.  
2.1. Determination of particle size and surface charge 
Average dimensions of SLN were evaluated by Dynamic Light Scattering (DLS), while Zeta potential 
was measured by laser Doppler velocimetry (LDV). For size measurement SLN dispersions were diluted 
(1:100) in bidistilled water, whereas for zeta potential measurement samples were diluted (1:20 or 1:50) 
in NaCl 1mM. All measurement were carried out on Malvern Zetasizer-Nano ZS (UK), in triplicate, at 
25°C. 
2.2. Chemical composition  
Chemical composition of carriers was assessed by HPLC-UV analysis: THA and protamine content 
was considered for determination of surface coating efficiency, whereas phosphatidylcholine (PC) content 
was used to check final composition of SLN (i.e. after washing steps) and chemical stability overtime. 
HPLC samples were prepared as follows: SLN were disrupted by dilution first with tetrahydrofuran and 
then with corresponding eluent (See supplementary material for chromatographic methods specifications). 
  
To establish the best conditions for electrostatic interaction between THA and SLN, several dilutions of 
SLN dispersions were incubated with different amounts of THA, and samples were then purified as 
previously described: the molar ratio among PC and THA in purified sample was determined by HPLC-
UV analysis. 
2.3. Morphological analysis 
Morphological characterization was performed by Field Emission Scanning Electron Microscopy 
(FESEM) (ZEISS Supra 40, DISAT, Polytechnic of Turin, Italy): SLN dispersions were diluted in a range 
1:500 to 1:5000 in bidistilled water, then 4µL were poured on a silica platelet and dried under light 
vacuum. Samples were observed at tension values ranging from 1 to 5 kV. 
2.4. DNA binding capacity 
The ability of cationic SLN to bind TFD was evaluated by gel retardation assay using agarose gel 
electrophoresis (See Methods in supplementary material for specific conditions). Evaluated samples were: 
TFD-SLN complexes, their corresponding samples after TFD extraction, and free TFD as control. For 
TFD extraction, SLN were disrupted by dilution with isopropanol and TFD was then precipitated by 
centrifugation (10000 rpm, 10 minutes, 4ºC). Two further washing steps with methanol were performed 
in order to solubilize THA and to release the TFD, followed by a centrifugation step, as previously 
described. Finally, precipitated DNA was resuspended in bidistilled sterile water. For SLN containing 
protamine, TFD was released by incubation with heparin solution (5 mg/mL) in a ratio 25:1 (w/w) with  
DNA, conditions in which heparin binds to the cationic polymer releasing the DNA [27]. 
 
3. Deoxyribonuclease I (DNase I) protection assay 
The protection of TFD against DNase I enzymatic activity was tested in reaction buffer rich in Mg
2+
 
and Ca
2+
, as those cations are essential for DNase I activity. EDTA solution was used at the end of the 
experiment to stop the enzymatic activity by chelation of these essential cations. 
TFD-SLN complexes dispersions were diluted in reaction buffer containing DNase I (1:4), samples 
were then incubated at 37°C for 30 minutes in an orbital shaker (350 rpm), and finally a volume of EDTA 
solution was added to stop the enzymatic activity. TFD was extracted from the complex and precipitated 
as described above. Samples were analyzed by agarose gel electrophoresis, as previously reported, to 
evaluate TFD integrity. First, increasing amounts of DNase I (0.01-1 U DNase I/µg TFD) were tested to 
find more adequate concentration needed to degrade a fixed amount of free TFD. Two types of controls 
were prepared with same amount of free TFD: negative control (non-degraded TFD), in which the stop 
solution was added at the beginning of the experiment, and a positive control, where TFD was fully 
degraded. The integrity of TFD-SLN complexes was evaluated by comparing with both controls. 
 
4. SLN interaction with bacteria 
  
To evaluate SLN ability to deliver TFD into bacteria, their interactions have been studied by confocal 
microscopy and flow cytometry. Selected SLN formulations with favourable stability and TFD protection 
were used for these studies and, in particular, SLN with two layers of THA and SLN with one layer of 
protamine, all of them at TFD concentration of 40 µg/mL (C-ON-C-Chol, C-ON-C-TP and ON-C-TPAP). 
Interactions were studied after 1h and 4h of incubation. 
4.1. Confocal microscopy 
For qualitative interaction studies by confocal microscopy, all tested SLN were labelled with the Infra-
Red dye, DiD (λex/em=644/663). Fluorescently labeled TFD (AF488 TFD) were used to prepare the 
complexes with SLN. Moreover, two control samples were included in the analysis: i) free TFD in water 
solution (to the same final equivalent concentration of 40 µg/mL); and ii) THA-TFD self-assembling 
nanoparticles, prepared and fully characterised as described by Marin-Menendez et al. [12]. Bacteria were 
stained with a wheat germ agglutinin lectin conjugated with tetra-methyl rhodamine (TMR WGA) 
fluorescent membrane dye (λex/em=555/580). 
E.coli strain DH5α was grown in LB broth until reaching an O.D. of 0.3 (630 nm), as described in the 
supplementary material (Supplementary Methods). This fresh culture was then incubated with SLN 
suspension (1:1 v/v) under gentle shaking at room temperature and in the dark for 1-4 hours. TMR-WGA 
dye (10 µg/mL) was added to the samples during the last 30 minutes of incubation in order to stain 
bacteria membranes.  
The samples were then spotted onto poly-lysine coated microscopy glass slides and left adhering for 1 
hour in a humid chamber in the dark. Glass slides were gently washed three times with sterile PBS, dried 
and mounted with Fluoroshield
®
 mounting media before they were covered with cover slips; they were 
then left 15 min for settling at room temperature in the dark and stored at 4⁰C overnight. Next day, the 
slides were analyzed by Leica SP5 confocal microscope using a 63x objective. The images obtained were 
processed with Image-J software (NIH Image). 
4.2. Flow cytometry 
Bacteria interaction with selected SLN formulations was also evaluated by flow cytometry.  
Bacteria cultures were incubated with SLN as described for confocal microscopy above. At the end of 
incubation, bacterial suspensions were pelleted (5 min, 4000g) and resuspended in an equal volume of 
PBS. Samples were then diluted in PBS (1:40) and measured with a FC500 flow cytometer (Beckman 
Coulter). 
The protocol for bacteria detection through flow cytometry was first optimized as fully described in 
Supplementary material (Table S1, Figures S6-S10). Briefly, the scatterplots (forward scatter, side scatter 
and fluorescence intensity) of unlabelled control bacteria were evaluated first. Then, bacteria were 
labelled with a WGA-AlexaFluor
®
 647 (λex/em=650/665, Life Technologies, UK) membrane dye to 
confirm the proper gating strategy and analyzed using FL4 laser (635 nm). Cells were then incubated with 
  
non-labeled SLN and the gates on the Forward Versus Side Scatter dot plots were once again adjusted to 
be sure to select only the bacteria population and eliminate debris due to residual SLN in solution.  
To quantify the signal of delivered TFD, C-ON-C-TP and ON-C-TPAP were loaded with fluorescent 
AF488 TFD, as for confocal microscopy analysis. In parallel, in order to quantify the signal of SLN 
interacting with bacteria, the lipid matrix was labelled with DiD.  
Single cells were gated using the FS vs SS scatterplots, previously optimized with non fluorescent SLN, 
and histogram on the corresponding Fluorescence channels (488 nm excitation FL1 laser for TFD and 
635 nm excitation FL4 laser for DiD) were used to evaluate the percentage of bacteria that were positive 
to TFD and to SLN signals respectively. Only the cells that were over the threshold set with control 
samples were considered in this calculation. The two analyses were performed separately in order to 
avoid problems of compensation among the two different fluorochromes. At least 10000 events were 
analyzed per condition. Results were analyzed with Kaluza software (Beckman Coulter, UK). 
 
5. Antibacterial activity 
5.1. Minimum Inhibitory Concentration (MIC) test 
Antibacterial activity of SLN was measured on Escherichia coli K12 strain (DH5α) using the minimum 
inhibitory concentration (MIC) assay. The standard broth microdilution method was in line with current 
Clinical and Laboratory Standards Institute (CLSI, USA) approved methodologies [28] and with the 
protocols previously described [29, 30]. Briefly, serial dilutions of Fur HP TFD-loaded SLN were 
incubated with a single clone of bacteria previously grown overnight on a fresh culture plate in an orbital 
shaker at 37°C for 14-18 hours. The final range of tested SLN concentrations was from 1300 µg/mL to 
0.65 µg/mL of PC (corresponding to THA concentration of 11µg/mL and 5.5 ng/mL in THA coated 
SLN). At the end of incubation, plates were evaluated visually and by reading the optical density (OD) at 
λ=630 nm with a plate reader (POLARstar Omega, BMG Labtech GmbH). MIC was considered as the 
concentration at which the OD was observed not to increase due to antibacterial activity of SLN. Each 
experiment was repeated in triplicate. 
5.2. MIC in iron-limited media  
The E. coli K-12 MG1655 strain was grown at 37°C in MOPS minimal media supplemented with 0.2% 
glucose (GMM) and 2 mM sodium nitrate. The media was stored under microaerobic conditions for 24h 
prior to use. Under these conditions MIC was determined by adding a range of concentrations of SLN 
under study to broth inoculated with MG1655, 1 x10
6 
colony-forming units (CFU) per mL. The final 
range of tested SLN concentrations was from 1000 µg/mL to 0.98 µg/mL of PC.  These were cultured for 
16 h under microanaerobic conditions before the concentration of bacteria (CFU/mL) was determined by 
plating of serial dilutions on LB agar plates and counting of subsequent bacterial colonies. Each 
experiment was repeated in triplicate. 
 
  
 6. In vitro and in vivo cytotoxicity studies 
6.1. Cytotoxicity MTT assay 
Caco-2 cells (colon adenocarcinoma cells, ATCC HTB-37) and Calu-3 cells (human epithelial lung 
adenocarcinoma cells, ATCC HTB-55) were cultured at 37ºC in Dulbecco’s Modified Essential Medium 
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 2% penicillin-
streptomycin. Cells were seeded in 96-well plates at 5 x10
4 
cells/cm
2
, left to grow until 70-80 % 
confluency and then culture media was removed and cells were incubated with 100 μL of serum-free 
media containing serial dilutions of the tested SLN formulations. Cells were incubated with the SLN for 
24h and 48h, then culture media was removed and MTT assay was performed . Briefly, cells were 
incubated with an MTT solution (400 μg/mL of MTT in media) for 2 hours at 37ºC. The MTT solution 
was then removed and 200μL of DMSO was added and the absorbance of the plates was read at 570 nm 
using a Luminometer (Glomax Explorer, Promega). Each experiment was performed three times; 
acetaminophen was used as a positive control of cytotoxicity. 
6.2. In vivo toxicity studies in Xenopus laevis embryo model 
All experiments were performed in compliance with the relevant laws and institutional guidelines at the 
University of East Anglia. The research has been approved by the local ethical review committee 
according to UK Home Office regulations. Xenopus laevis embryos were obtained as previously 
described [31]. Embryos were grown at 23ºC until they reached stage 38, and then plated in 48-well 
plates (5 embryos/well, n=15 used for each condition) in 0.1X MMR media containing the serial dilutions 
of SLN at 6 different PC concentrations (from 1.5 mg/mL to 46.8 mg/mL) and incubated at 18ºC. Non-
treated embryos were used as control. The mortality and the morphological changes of the embryos were 
recorded every 24h until embryos reached stage 45. The experiment was repeated twice. 
 
7. Statistical analysis 
Statistical analysis of data was performed using GraphPad Prism Software v7.04. 
 
RESULTS AND DISCUSSION 
1. SLN preparation and characterization 
Different SLN were successfully obtained by warm microemulsion method with different lipid matrices 
and combinations of surfactants and co-surfactants. These SLN were then used as a scaffold for their 
further coating with THA and TFD. As shown in Table 2, the particles presented a size around 100 nm 
and negative zeta potential. Incorporation of ascorbyl palmitate (A-TPAP) made the particles slightly 
bigger but with a lower negative zeta potential, an effect that has been previously reported for other lipid 
nanocarriers containing ascorbyl palmitate [32, 33]. Coating with THA did not affected size, but caused 
inversion of zeta potential from negative to positive, due to effective interaction between the cationic 
compound and SLN surface. Coating with protamine showed similar behavior.  
  
THA coating efficiency was very high, with a value of association to SLN equal to 88% ± 5% for C-
Chol and 89% ± 6% for C-TP. Furthermore, recurrent value for molar ratio between PC and THA was 
found, around 3.6%± 0.3% (n=5) for all different THA concentrations tested, suggesting concentration 
saturable loading of THA into the SLN matrix surface. This trend was found for both SLN compositions 
and it was taken as reference value in optimization of layering process, purification and scaling studies.  
Protamine content was analyzed  by HPLC; the interaction of the polypeptide with SLN surface was 
also high, with 64 ± 4% of the initial protamine detected after TFF washing step, which is in agreement 
with data reported for other lipid nanocarriers containing PEG stearate [34]. 
The incubation with TFD (final concentration 10 µg/mL) slightly reduced zeta potential of SLN coated 
with cationic molecule. The molar ratio between the bolaamphiphile and the oligonucleotide was 
determined as 964:1 for ON-C-Chol and 988:1 for ON-C-TP, which implies a positive-to-negative charge 
ratio Z+/-=13. In the case of protamine coated SLN, the molar ratio between the polypeptide and TFD was 
112:1, which leads a positive-to-negative charge ratio Z+/-=14.5. Absence of complexes between THA or 
protamine and TFD was confirmed by DLS analysis and gel filtration chromatography. Briefly, 
fluorescent dye (DiO) was loaded into SLN matrix as a particle marker, and fluorescent TFD-loaded SLN 
were loaded into Sepharose CL-4B column (28cm), then fractions of 1mL were collected from the 
column over time. Analysis of the eluted fractions showed the presence of TFD only in the fractions 
where SLN were recovered, confirmed by HPLC determination of SLN components (PC, THA or 
protamine) and the fluorescent marker DiO by UV-Vis spectrophotometry, being a further confirmation 
of effective complexation between TFD and SLN. Moreover, no complexes between THA/protamine and 
TFD were detected in any of the eluted fractions. 
Images by Field Emission Scanning Electron Microscopy (FESEM) showed that SLN had a round 
shape and suggested the presence of populations of different size, which would be in agreement with the 
polydispersity indices (0.2 <PdI<0.26) obtained by DLS analysis.. Representative images of anionic SLN 
A-Chol and A-TP, as well final formulation C-ON-C-Chol and C-ON-C-TP that will be described later 
have been obtained (Figure 1).  
 
2. DNA binding capacity of THA-SLN cationic complexes 
The visualization of agarose gel after electrophoresis showed ON-C-TPAP were able to effectively bind 
all the added TFD (10 µg/mL), whereas for ON-C-Chol and ON-C-TP SLN a band of free TFD appeared, 
much more evident in ON-C-Chol (Figure 2). In order to reduce free TFD, small amount of THA was 
added over TFD layer, forming further external THA coating. 
As expected, the addition of further THA layer is an efficient way to increase TFD binding capacity, 
with no band of free TFD at all concentrations tested (100-320 µg/mL THA) (Figure 2). The lowest 
concentration of THA in the second layer was selected for biological studies because of safety 
considerations.  
  
As shown in Table 3, SLN with double THA layers displayed no changes in size and PdI and only a 
slight increase in positive zeta potential was observed (from +16 mV to +18 mV in C-ON-C-Chol and 
from +14 mV to +18 mV in C-ON-C-TP). The total amount of THA in the final SLN was comparable in 
both SLN types, ratio between THA and PC raised up to 5% ± 1 % (n=6) in both cases. The molar ratio 
between the bolaamphiphile and the oligonucleotide was raised to 1073:1 for C-ON-C-Chol and 1052:1 
for C-ON-C-TP, which gives a positive-to-negative charge ratio Z+/-=14, comparable to value found for 
protamine-coated SLN. 
Furthermore, to determine the maximum amount of TFD that could be attached to SLN surface, ON-C-
Chol and ON-C-TP were successfully prepared with increasing amounts of TFD, starting from 
concentration 10 µg/mL and increasing 16-fold. Then, second coating with THA was applied to TFD 
layer. Increasing TFD amount did not change the SLN size and PdI at all concentrations tested, whereas Z 
potential decreased as TFD content increased, reaching values close to neutrality (Chol matrix) or even 
negative (TP matrix) for the highest concentration tested. Second layer of THA did not affect particle 
size, zeta potential was positive with very similar values in all cases (See supplementary material, Figure 
S1). 
Agarose gel electrophoresis (Figure 3) showed both kinds of SLN were able to bind up to 5 times more 
TFD by increasing it concentration, and no TFD free band was seen after the addition of THA second 
layer. A further increase in TFD concentration showed a band of free TFD. This free TFD was again 
more evident in ON-C-Chol SLN type. Formulations showing more free-TFD displayed lower values of 
positive zeta potential, which could indicate only partial coating of underlying TFD layer. Finally, 
samples containing 40 µg/mL of TFD were selected for further studies. In this case molar ratio between 
THA and TFD was reduced to 266:1 for both SLN types (Chol and TP), which reaches Z+/-=3.5. 
For comparative purpose, ON-C-TPAP (protamine) was evaluated for its ability to bind higher amounts 
of TFD. The behavior was the same as for other 2 prototypes, with reduction of positive zeta potential at 
increasing amount of TFD, without significant changes in size. The agarose gel after electrophoresis did 
not show free TFD band in the range of tested concentrations (10-40 µg/mL TFD). For ON-C-TPAP 
containing 40 µg/mL of TFD, the molar ratio between protamine and ON was 28:1, with Z+/-=3.6. These 
data confirm that final positive-to-negative ratio was comparable for all 3 TFD-SLN complexes prepared, 
although differences in composition and in cationic moieties used for coating. 
 
3. DNase I protection studies 
A crucial characteristic of DNA carriers is their ability to protect DNA from enzymatic degradation by 
DNase, improving chances of cellular internalization and maintaining transfection efficacy [35, 36]. The 
amount of DNase I needed to degrade free TFD in appropriate experimental timescales was first assessed 
by screening enzyme masses ranging from 0.01 to 1U DNase I per 1 µg of TFD. Agarose gels 
electrophoresis of these samples showed that 0.2 U DNase I per µg of TFD produced a partial degradation 
  
in 30 minutes, and gradual increase in concentrations led to full digestion of nucleic acids (data not 
shown). 0.6 U DNase I per µg of TFD was finally selected as the optimal enzyme amount to ensure total 
degradation of free TFD. Unbound TFD is degraded by the enzyme into smaller fragments that run farther 
compared to intact TFD (Figure 4 lanes A1 and B1) that also showed reduced fluorescent band intensity 
(Figure 4 lanes A2, A7, and B2). For ON-C-Chol (Figure 4A), absence of THA second layer led to TFD 
degradation (Figure 4A lane 4 compared to 3, non-treated SLN), while particles with external THA layer 
(C-ON-C-Chol) were able to protect TFD at both concentrations tested, 10 and 40 µg/mL. No difference 
in band intensity was observed between non-treated and treated samples after the effective extraction of 
TFD from the complexes (Figure 4A lane 6 compared to lane 5 for 10 µg/mL; lane 9 compared to lane 8 
for 40 µg/mL). The same behavior was observed for ON-C-TP (Figure 4B): absence of THA external 
layer caused bigger TFD degradation (Figure 4B lane 4 vs lane 3), whereas THA second layer preserved 
TFD after incubation with DNase I at both tested concentrations (Figure 4B lane 6 vs lane 5 and lane 9 vs 
lane 8).  
These results suggest that external THA generates full TFD protection against enzymatic degradation, 
probably because of improved hiding and condensed state of TFD, a structural conformation which may 
help in making it refractory to DNase I. These observations are consistent with published circular 
dichroism spectroscopy data demonstrating DNA condensation by 12-bis-THA [37, 38].  
Enzymatic degradation assay carried out on ON-C-TPAP at highest concentration (40 µg/mL TFD) also 
showed TFD was fully protected from enzyme (See supplementary material, figure S2), in agreement 
with data previously reported for other gene carriers based on protamine [39-41].   
 
4. SLN interaction with bacteria 
4.1. Confocal microscopy 
Confocal microscopy analysis of SLN-bacterial interactions was permitted by successful SLN labeling 
with DiD. Dye entrapment efficiency was very high (>95%), and labeling proved to be stable after 
washing 6x with TFF (data not shown). Before incubation with bacteria C-ON-C-Chol, C-ON-C-TP and 
ON-C-TPAP were complexed with 40 µg/mL of fluorescent Fur HP AF488TFD (AF488-TFD) and 
validated by DNase I protection assay (data not shown), as previously reported for non-fluorescent TFD. 
Neither the different TFD nor the addition of the fluorescent dye affected overall physicochemicals 
characteristics of SLN. 
Representative images of SLN interaction with bacteria were obtained after 1 and 4 hours of incubation 
(Figure 5 and figure S3). Bacteria, here labeled with the red WGA membrane lectin dye, can be seen 
adhered to the glass slides. As expected, the extent of interaction between bacteria and anionic SLN (A-
Chol, A-TP and A-TPAP) was quite low up to 4 hours. This was most likely due to repulsive forces 
between the negatively charged SLN and the bacterial membranes (Figure 5A, A’ D, D’, G and G’). 
  
In contrast, cationic SLN displayed rapid and extensive interaction with bacterial cells, independent of 
their lipid composition. This was observed for THA coated C-Chol and THA coated C-TP as well as for 
protamine coated C-TPAP: all displayed extensive membrane binding and cellular aggregation especially 
after 4h incubation (Figure 5 B’, E’ and H’). For all the different samples the signal of the DiD, labeling 
lipid matrix of SLN, was mostly observed interacting with the external surface of the bacteria and very 
low intracellular particle delivery could be observed at both time points (1 and 4 h). This can be 
appreciated even better in figure S3 that reports the three fluorescence channels separated.  
Although the lipid core did not influence the SLN-bacteria interaction, it seemed to have an important 
role in determining the TFD intracellular delivery. Specifically, when incubating bacteria with the 
cholesteryl ester based C-ON-C-Chol, most of the SLN and TFD signal is observed around the membrane 
without penetrating into the cytoplasm (blue and green signal in Figure 5C and C’). Here, a high 
colocalization between membrane, SLN and TFD dyes was observed at both time points of analysis 
(yellow signal in figure 5C and C’). Interestingly, more extensive TFD intracellular signal was observed 
with tripalmitin based C-ON-C-TP and ON-C-TPAP. For C-ON-C-TP SLN, a strong membrane affinity 
was still observed for the first time point of analysis (Figure 5F and figure S3 D-F), whereas after four 
hours of incubation, the intracellular signal seems higher and in some cases the oligonucleotide signal 
was observed diffused in the bacteria cytoplasm (Figure 5F’ and I’, S3 D’-F’ and G’-I’), effect that was 
observed since the first time point (Figure 5I) in the case of ON-C-TPAP. In these cases, a low 
colocalization was observed between TFD and SLN signals, suggesting that the SLN-TFD complex is 
disrupted during TFD uptake.  
4.2. Flow Cytometry  
Semi-quantitative data of SLN interaction with bacteria were obtained by flow cytometry. Only 
tripalmitin based SLN were used for these experiments, as they resulted the most promising agent in 
terms of intracellular TFD delivery by confocal microscopy. As fully described in supplementary 
material, acquisition parameters were optimized on control cells and SLN alone to allow specific 
identification of the bacteria population and to quantify the interaction between bacteria and the delivery 
system. 
To evaluate TFD delivery by flow cytometry, SLN were prepared with fluorescently labelled AF488-
oligonucleotides and incubated with cells for 1 and 4h. In a separate set of experiments, the lipid matrix 
was labelled with DiD and the SLN-bacteria interaction was measured, in order to avoid problems related 
to non-specific fluorescence detection between the different channels. In agreement with confocal 
microscopy data analysis, flow cytometry confirmed that interaction with anionic SLN is very low at both 
time points, with less than 5% of gated events interacting with DiD labelled SLN even after 4 hours of 
incubation (FL4 laser, 635nm excitation) (Table 4). This underlines the importance of the positive charge 
in triggering bacteria uptake. After bacteria incubation with cationic SLN (C-ON-C-TP and ON-C-
TPAP), a rapid increase in the proportion of positive gated cells was observed. The percentage of stained 
  
bacteria for C-ON-C-TP was 65% after 1h of incubation and almost 70% after 4 hours.  The percentages 
were slightly higher for ON-C-TPAP, with 69% and 73.5% of stained bacteria after 1h and 4h of 
incubation respectively. 
Results are different when measuring the TFD signal on FL1 channel (488nm excitation), as only 
12.5% and 30.4% of cells were above the threshold that was considered as positive to TFD signal after 1h 
of incubation with both C-ON-C-TP and ON-C-TPAP. After 4 hours of incubation, these percentages 
increased up to 21.7% in the case of C-ON-C-TP whereas remained almost unaltered for ON-C-TPAP 
(31.2%). The increase observed for C-ON-C-TP might suggest that fluorescence of TFD is somehow 
quenched at early time points, when it was observed that TFD are still interacting with bacteria 
membranes. After 4 hours of incubation, the intracellular diffusion of the TFD is also observed by 
confocal microscopy, might lead to dequenching of the TFD signal and a consequent higher percentage of 
stained bacteria. This was also tested by measuring the fluorescence of SLN in a liquid suspension 
(Figure S5). Here it was shown that, when interacting with THA, TFD fluorescence is actually quenched. 
Only when THA-TFD interaction is disrupted the fluorescence is fully recovered. The same could happen 
in cells, where only the SLN outer layer of THA is removed or somehow sequestered by the cells, then 
TFD is released and fluorescence is dequenched.  
On the other hand, confocal microscopy analysis showed that the release of TFD when incubating 
bacteria with ON-C-TPAP seemed faster, thus limiting the quenching effect described for C-ON-C-TP. 
This might explain the higher percentage of TFD positive cells measured by flow cytometry after 1hour 
of incubation, which is almost the same after longer incubation times. Methodological differences and 
sample sizes in respective methods nonetheless precludes direct comparison between confocal 
microscopy and flow cytometry analyses. Even if techniques that allow to obtain semi quantitative 
evaluations of nanoparticles-cell interactions also at a subcellular level are now widely diffusing [42-45], 
in the present work the focus of confocal microscopy analysis was only for a qualitative study of SLN-
bacteria interaction and the subsequent TFD intracellular release. Flow cytometry analysis completed 
confocal microscopy data with a semi-quantitative evaluation of the SLN-bacteria interactions, but did 
not allow us to discriminate if the oligo was intracellularly released or remained interacting with the 
membrane, as no strategies to distinguish between interacting and internalized SLN were developed in the 
present study. 
Overall, these results confirm that both THA and protamine are cationic agents that lead to a high 
interaction between SLN and bacteria. Moreover, the intracellular release of TFD, even if it was observed 
in a reduced number of bacteria, seemed to be improved when tripalmitin was used as lipid core. The 
exploitation of super-resolution microscopy techniques would further illuminate the entry pathways and 
mechanics of SLN penetration into bacterial cells. 
 
5. Antibacterial activity 
  
The TFD used in this study (Fur HP TFD) targets the Fur transcription factor that controls iron 
homeostasis in E. coli and other bacteria [23]. TFD mediated inhibition of Fur is expected to deregulate 
iron-transport mechanisms and curtail response to concomitant oxidative and nitrosative stress, and would 
be expected to prevent bacterial growth under microaerobic conditions in iron-limited media 
supplemented with 2 mM nitrate. These conditions mimic those likely to be found in infected parts of the 
body and so they can be taken for testing whether Fur is a target for virulence modulation, as predicted by 
animal models [46]. For this reason, we investigated the antimicrobial activity of select SLN under these 
conditions, results are shown in Figure 6. As expected, there was no measurable decrease in bacterial 
colonies at the end of the experiment for SLN lacking TFD (C-Chol, C-TP and C-TPAP) over a wide 
range of concentrations of SLN (0.975 to 1000 µg/mL PC) comparing with untreated control. In contrast, 
noticeable antibacterial activity was seen for other three SLN formulations, with plots showing a >2 log 
reduction in surviving bacterial at concentrations above 200 µg /mL PC with MIC values of 15.6 µg/mL 
for C-ON-C-Chol (corresponding to 0.07 µg/mL of TFD and 0.44 µg/mL of THA respectively), 3.9 
µg/mL for C-ON-C-TP (corresponding to 0.02 µg/mL of TFD and 0.12 µg/mL of THA) respectively and 
3.9 µg/mL for ON-C-TPAP (corresponding to 0.02 µg/mL of TFD).  
These special conditions allowed to measure TFD specific contribution because under aerobic 
conditions it was not observed any TFD-mediated killing, as Fur is not an essential transcription factor 
and the anti-bacterial activity observed was due to the contribution of THA (Table S2). Interestingly, in 
anaerobic conditions MIC values were much lower than in aerobic experiments. In terms of PC, it can be 
noticed that the MIC of SLN containing THA went from 22 to 15.6 µg /mL in C-ON-C-Chol, and from 
39 to 3.9 µg /mL in C-ON-C-TP with a surprising 10 fold reduction. TFD contribution was stronger in C-
ON-C-TP than in C-ON-C-Chol most likely due to the higher intracellular release of TFD, as previously 
confirmed by confocal microscopy (Figure 5F’).  
 Even more strikingly, when ON-C-TPAP SLN were used in aerobic conditions it was barely observed 
any MIC, as no THA was present. However, when incubating the bacteria in anaerobic conditions MIC 
went down from 700 µg /mL to 3.9 µg /mL of PC, the same value observed for C-ON-C-TP SLN. These 
results are again in accordance with confocal microscopy analysis, which showed a high TFD 
intracellular signal in bacteria incubated with ON-C-TPAP (Figure 5I and I’).  These data further 
demonstrate the specific action of TFD when they are efficiently released from SLN inside bacteria. 
 In order to further confirm whether the antibacterial activity was due to the specific action of the TFD 
inhibiting Fur activity, a comparative study was performed with C-TPAP SLN loaded with a scrambled 
version of the Fur TFD, referred to as Scr Fur HP TFD (See Supplementary Materials). This has the same 
nucleotide content of the Fur HP TFD, and will similarly form a double-stranded hairpin structure but has 
been designed to destroy the binding site for the Fur transcription factor to render it inert. Under 
microanaerobic conditions no discernable antibacterial activity was detected, with not more than 1-log 
  
reduction in CFU/mL detected for the highest concentration tested, which was 1000 ug/mL PC (See 
Supplementary results, Figure S11).  
 
6. In vitro and in vivo cytotoxicity studies 
6.1. SLN cytotoxicity evaluation by MTT assay 
Mindful of the need to consider the biocompatibility of any experimental antibacterial, SLN 
formulations were assessed for toxicity using the MTT assay using one gastrointestinal and one lung 
epithelial cell line as models of two frequent infection sites. The IC50 values obtained in both cellular 
lines Caco-2 and Calu-3 for SLN formulations tested are summarized in Table 6 (cell viability vs. 
concentration plots are available in supplementary material, Figure S9). The IC50 values are reported in 
PC units (mg/mL) and THA units (μg/mL), for comparison between SLN formulations, protamine 
concentrations (μg/mL) are reported for SLN not containing THA (Table 5). Results show that A-Chol 
and A-TP (anionic) caused no decrease in the extent of MTT turnover in Caco-2 or Calu-3 cell lines, 
either after 24h or 48h. On the other hand, C-ON-C-Chol and C-ON-C-TP (both containing THA and 
TFD) showed the lowest IC50 values in both cell lines and time points assessed. Finally, A-TPAP and 
ON-C-TPAP showed similar IC50 values despite their opposite charges; ON-C-TPAP was markedly less 
cytotoxic than cationic analogues C-ON-C-Chol and C-ON-C-TP (THA double layer). 
Overall, IC50 values from MTT assays were much higher than MIC values. This selectivity for bacterial 
activity over mammalian toxicity ranged from 4-12 times for C-ON-C-Chol, 23-100 times for C-ON-C-
TP and >175 times in the case of ON-C-TPAP. 
 
6.2. In vivo toxicity of SLN on Xenopus laevis embryo model assay 
The Xenopus laevis larvae model was used to assess the toxicity of SLN formulations in order to obtain 
a robust toxicity profile of anionic and cationic SLN. This model has been previously proposed as a 
suitable high throughput screening model to fill the gap between the in vitro and in vivo mammalian 
toxicity models [31, 47, 48]. 
The cumulative percentage survival of stage 45 embryos after 96h exposure to different SLN is shown 
in Figure 7. At concentrations of 46.8 μg/mL PC no effect on larvae survival was observed. At higher 
concentrations (starting from 187.5 μg/mL of PC), more than 10 times the MIC, these SLN elicited some 
reduced larval survival (42% for C-ON-C-Chol and 24% for C-ON-C-TP), which is related only to the 
presence of THA (Figure 7). For SLN bearing cationic charge by virtue of protamine coating, larvae 
survival was only compromised after exposure to the highest tested dose (1500 µg/mL PC). This whole 
organism toxicity is unlikely attributable to particle cationic charge, as the corresponding anionic SLN 
showed a very similar toxicity profile. Specifically, the negatively charged A-Chol and A-TP SLN caused 
almost no effect on the larvae survival even after incubation with the highest concentration (1500 µg/mL 
  
PC) at the assessed stages (from stage 38 to stage 45).These results are consistent with the toxicity trends 
observed by MTT assay.  
Representative images of the embryos exposed to SLN at 187.5 μg/mL of PC are shown in 
supplementary material (Figure S13). All embryos show the same phenotype as the control with the 
exception of the C-ON-C-Chol and C-ON-C-TP treated embryos which were morphologically affected by 
the SLN. The majority of the abnormalities observed were stunted growth/development and bent spine. 
 
CONCLUSIONS 
This work describes a number of formulations of cationic coated SLN for the association, protection 
and delivery of antimicrobial oligonucleotides (TFD) as an alternative solution to the increasing health 
threat of antimicrobial resistances. Beyond this, the data reported here underlines the possibility of 
obtaining complexes between TFD and several cationic SLN differing in the nature of the cationic coating 
(THA, protamine) which displayed robust DNA interaction that afforded DNAse protection in vitro. 
Moreover, the interaction between TFD-SLN complexes and bacteria showed effective TFD intracellular 
delivery and specific antibacterial activity under Fe limiting conditions, showing a good safety profile to 
eukaryotic cells at the concentrations needed for antibacterial activity. Although obtained results require 
further investigation, mainly to test efficacy in pathogenic bacteria strains, this work demonstrates the 
possibility of creating a good interaction between cationic lipid nanocarriers and oligonucleotides and 
supports the potentiality of such new approaches to fight drug resistance in bacteria.   
 
SUPPLEMENTARY MATERIAL 
Following supplementary material is available (pdf): TFD sequences, chromatographic methods, 
additional synthetic procedures, details on TFD interaction with cationic SLN, Flow Cytometry 
optimization and scatterplots, additional results of biological evaluation of TFD-SLN complexes. 
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Figure 1. Field Emission Scanning Electron Microscopy (FESEM) images: 1) Anionic SLN prepared 
with a mixture of cholesteryl ester (A-Chol, top left image) or with tripalmitin (A-TP, top right image); 2) 
final cationic SLN containing TFD and double layer of THA with a mixture of cholesteryl ester (C-ON-
C-Chol, bottom left image) or with tripalmitin (C-ON-C-TP, bottom right image) Images were captured at 
1-5 kV. 
 
Figure 2.  Agarose gel electrophoresis of SLN having decreasing amount of THA for second layer 
coating. Lane 1 correspond to free TFD control (10 µg/mL); Lanes 2 and 7 correspond to ON-C-TP and 
ON-C-Chol respectively; Lanes 3-6 and 8-11 correspond to SLN with the second coating of THA in 
concentrations ranging from 320 to 100 µg/mL. Arrows indicate lanes in which free TFD band was 
observed. 
  
 
 
Figure 3.  Agarose gel electrophoresis of cationic THA-SLN incubated with increasing amount of TFD: 
4A) ON-C-Chol, 4B) ON-C-TP. Lane 1 correspond to free TFD control (10 µg/mL) *THA second 
coating added. 
 
 
 
 
 
 
 
  
Figure 4.  DNase I protection assay. Agarose gel electrophoresis: Lanes A1 and B1 correspond to 
negative control, whereas lanes A2, A7 and B2 correspond to positive control. A) ON-C-Chol and C-ON-
C-Chol, B) ON-C-TP and C-ON-C-TP (*indicates run of TFD extracted from the corresponding sample). 
Continuous line indicates intact DNA, dots line indicates degraded DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5. Confocal microscopy images. Interaction between E.coli DH5α bacteria and different types of 
SLN after 1h and 4h of incubation. Bacteria membranes are visualized in red, DiD labelled SLN in blue 
and Fur HP AF488 TFD in green. (Scale bar= 2µm). 
 
 
Figure 6. Antimicrobial properties of TFD loaded SLN. The number of surviving E. coli colonies 
(CFU/mL) were counted following growth in microaerobic conditions in a minimal media supplemented 
with 10 µM FeSO
4
 and 2 mM nitrate at 37°C for a 16h period. The media contained varying 
concentrations of SLN as reported by PC concentration (µg/mL). Starting inoculum was 1 x10
6 
CFU/mL.  
 
  
 
Figure 7. Xenopus laevis nanotoxicity assay after exposure to A-Chol, A-TP, A-TPAP, ON-C-TPAP, C-
ON-C-Chol and C-ON-C-TP:  Xenopus laevis larvae survival after SLN exposure from stage 38 to stage 
45 at 18ºC (n=30 for each concentration). 
 
 
  
  
 
 
Table 1. SLN prototypes composition and codification according to layers composition 
Lipid 
Matrix 
Type of SLN and layers composition 
Anionic 
Addition of 
cationic 
compound 1
st
 
layer  
Cationic, 
single 
layer 
TFD 
addition 
Cationic, 
single layer, 
TFD loaded 
Addition 
of 
cationic 
compound 
2
nd
 layer 
Cationic, 
double layer, 
TFD loaded 
Cholesteryl 
esters 
mixture 
A-Chol 
→ 
+ THA 
C-Chol 
→ 
+  TFD 
ON-C-Chol 
→ 
+ THA  
C-ON-C-Chol 
Tripalmitin A-TP 
→ 
+ THA 
C-TP 
→ 
+  TFD 
ON-C-TP 
→ 
+THA 
C-ON-C-TP 
Tripalmitin 
and 
Ascorbyl 
palmitate 
A-
TPAP 
→ 
+ PROT 
C-TPAP 
→ 
+  TFD 
ON-C-TPAP - - 
THA: 12-bis-THA-Cl; PROT: Protamine 
 
Table 2. Physicochemical characterization of SLN: size (nm), PdI and Zeta potential (mV) determined by 
DLS (Values are mean ± SD (n=3-20)) 
Lipid matrices SLN ID 
Layers composition SLN physicochemical properties 
THA Protamine TFD Size (nm) PdI 
Z potential 
(mV) 
Cholesterol ester 
mixture 
A-Chol - - - 90 ± 5 0.224 -19 ± 5 
C-Chol Y - - 91± 6 0.235 +16 ± 2 
ON-C-Chol Y - Y 91 ± 2 0.249 +14 ± 3 
Tripalmitin 
A-TP - - - 101 ± 10 0.265 -21 ± 5 
C-TP Y - - 93 ± 10 0.267 +14 ± 3 
ON-C-TP Y - Y 90 ± 3 0.285 +12 ± 2 
Tripalmitin 
+ 
ascorbyl palmitate 
A-TPAP - - - 119± 12 0.282 - 28 ± 3 
C-TPAP - Y - 124 ± 14 0.272 +12 ± 1 
ON-C-TPAP - Y Y 110± 11 0.280 +10± 3 
Y: component present. SigH DB TFD concentration used was 10 μg/mL 
 
  
Table 3. Physico-chemical characteristics of SLN before and after second coating with THA (100 
µg/mL): size (nm), PDI and Zeta potential (mV) determined by DLS; THA and PC final concentration 
determined by HPLC (Values are mean ± SD (n=7)) 
Y: 
component present. SigH DB TFD concentration used was 10 μg/mL 
 
 
Table 4.  Quantitative evaluation of SLN interaction with bacteria after 1h and 4h of incubation: 
percentage of bacteria positive to the TFD, labelled with AF488, and positive to SLN, labelled with DiD. 
Samples TFD (AF488, %) SLN (DiD, %) 
 
1h 4h 1h 4h 
Control 0.42 0.12 0.1 0.81 
A-TP 0.01 0.01 1.13 2.8 
C-ON-C-TP 12.5 21.69 65.06 69.69 
A-TPAP 0.31 0.43 1.6 4.02 
ON-C-TPAP 30.36 31.16 68.86 73.5 
 
 
Table 5.  Cytotoxicity - IC
50
 values obtained for SLN formulations incubated with Caco-2 and Calu-3 
cells for 24h and 48h (Data represent means ± SD of three independent experiments). 
Samples IC50 
SLN 
Layers Composition 
Physical and Chemical Properties 
DLS HPLC (UV-vis) 
THA 
1
st 
layer 
 
TFD  
THA 
2
nd 
layer 
 
Size  
(nm) 
PdI 
Z Pot  
(mV) 
THA 
(µM) 
PC  
(mM) 
C-Chol Y - - 
91± 6 0.235 +16 ± 2 405± 2 11.3 ± 0.9 
ON-C-Chol Y Y - 
91 ± 2 0.249 +14 ± 3 nd nd 
C-ON-C-Chol Y Y Y 
97 ± 7 0.227 +18 ± 1 451± 2 9.5± 0.9 
C-TP Y - - 
93 ± 10 0.267 +14 ± 3 415± 2 11.3 ± 1.2 
ON-C-TP Y Y - 
90 ± 3 0.285 +12 ± 2 nd nd 
C-ON-C-TP Y Y Y 
92 ± 7 0.268 +18 ± 1 442± 3 8.8 ± 0.9 
  
SLN 
component 
(concentration) 
Caco-2 Calu-3 
24h 48h 24h 48h 
A-Chol PC (mg/mL) n.d. n.d. n.d. n.d. 
C-ON-C-Chol 
PC (mg/mL) 0.18 ±0.07 0.10 ±0.03 0.10 ±0.07 0.06 ±0.05 
THA (µg/mL) 6.23 ±0.86 3.93 ±2.11 4.15 ±3.54 2.74 ±2.93 
A-TP PC (mg/mL) n.d. n.d. n.d. n.d. 
C-ON-C-TP 
PC (mg/mL) 0.39 ±0.14 0.21 ±0.08 0.11 ±0.07 0.09 ±0.01 
THA (µg/mL) 17.22 ±6.92 8.98 ±3.39 4.83 ±3.17 3.91 ±0.18 
A-TPAP PC (mg/mL) n.d. 1.00 ±0.27 0.84 ±0.21 0.87 ±0.17 
ON-C-TPAP 
PC (mg/mL) 3.07 ±0.77 1.10 ±0.27 0.68 ±0.41 0.89 ±0.12 
Prot (µg/mL) 130.2 ±30.6 47.1 ±12.2 29.6 ±18.3 37.8 ±4.9 
n.d. IC50 not determined 
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